Freenome, Inc. (Nasdaq: FRNM) SEC filings document the company’s public-company disclosures as an early cancer detection business developing blood-based screening tests. The most relevant filings cover registration activity, business-combination history, material events, capital structure, governance matters, clinical and regulatory disclosures, operating results, and financial results.
Freenome entered the public market through a business combination with Perceptive Capital Solutions Corp., a blank-check company, after which the combined company took the Freenome, Inc. name. Its registration statements and material-event reports carry the detail behind that transition, the resulting share structure, and the securities registered for resale by selling securityholders.
For Freenome, clinical and regulatory filing language is especially important because the company’s disclosed business depends on blood-based cancer screening tests, FDA status, and commercialization arrangements. Investors may review filings for discussion of SimpleScreen™ CRC, SimpleScreen™ Lung, FDA-related disclosures, technology descriptions, risk factors, material agreements, and financial reporting.
Quarterly reports, annual reports, registration statements, proxy materials, Form 4 insider-transaction filings, and Form 8-K material-event reports can each answer different questions when they are filed. For Freenome, these documents may show how the company describes its multiomics platform, Abbott commercialization agreement, governance structure, capital structure, operating results, and clinical or regulatory matters.
Freenome, Inc. files an amendment to provide full interim financials and MD&A for Freenome Holdings, Inc. ahead of and around its July 20, 2026 business combination with Perceptive Capital Solutions Corp., which was accounted for as a reverse recapitalization.
For the six months ended June 30, 2026, Freenome generated $6.5 million in revenue, primarily from a major collaboration with Exact Sciences plus U.K. test sales, versus $1.5 million a year earlier. Net loss widened to $132.6 million, with $97.1 million of cash used in operating activities, reflecting heavy R&D and G&A spending.
At June 30, 2026 Freenome reported total assets of $398.5 million, including cash, cash equivalents and short-term marketable securities of about $102.0 million, deferred revenue of $71.1 million tied mainly to the Exact Sciences license, and significant lease and cloud-service commitments. Management states that existing liquidity plus $295.5 million in net proceeds from the SPAC/PIPE transaction is expected to fund operations for at least 12 months from issuance.
Freenome, Inc. received an updated Schedule 13G/A from IPConcept (Luxembourg) S.A. and BIT Global Technology Opportunities SICAV-FIS regarding Class A Ordinary Shares, par value $0.0001 per share, CUSIP G70077105.
Both Luxembourg-based reporting persons state that they now beneficially own 0 shares of this class, representing 0% of the outstanding Class A Ordinary Shares. They report no sole or shared voting power and no sole or shared dispositive power over any Freenome Class A Ordinary Shares, indicating that they no longer hold a reportable position in this security.
Perceptive Capital Solutions Corp received an ownership update from 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman. The filing states that these reporting persons do not beneficially own any Class A ordinary shares of the company, resulting in a reported 0 shares and 0% of the class held. The amendment reflects that their holdings have fallen to 5% or less of the class, and all sole and shared voting and dispositive powers are reported as zero. The reporting persons list their principal business address as 1700 Broadway, Suite 4200, New York, New York 10019, and the issuer’s principal executive offices as 51 Astor Place, 10th Floor, New York, New York 10003.